Drug Clinical Trials List
Drug Clinical Trials List
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| Phase II study of the efficacy of metronomic capecitabine chemotherapy as a maintenance treatment in advanced triple negative breast cancer | King Abdullah Medical City | Ongoing | Capecitabine | 2 | 20-611 | King Abdullah Medical City (Makkah) |
| Phase I/II Study of a Lentigen® CD19 Chimeric Antigen Receptor (CAR) T Cells in Adult patients with relapsed/refractory CD19 Positive Non-Hodgkin’s Lymphoma (NHL) using a Closed Transduction System | King Faisal Specialist Hospital and Research Centre | Completed | CD19-CART | 1, 2 | 2191301 | KFSH&RC-R |
| Phase I/II Study of a Lentigen® CD19 Chimeric Antigen Receptor (CAR) T Cells in Adult patients with relapsed/refractory CD19 Positive Acute Lymphoblastic Leukemia (ALL) using a Closed Transduction System | King Faisal Specialist Hospital and Research Centre | Completed | CD19-CART | 1/2 | 2191207 | KFSH&RC-R |
| Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%) | Pfizer | Ongoing | PF-07055480 (formerly SB-525) | 3 | C3731003 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C<2%) (BeneGene-2) | Pfizer | Ongoing | PF-06838435 | 3 | C0371002 | KFSH&RC-R |
| "Phase 2, Single-Site, Open-Label, Randomized, 2-Arm Parallel Study to Assess the Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS" | Eagle Pharmaceuticals | Completed | Dantrolene | 2 | EGL-4104-C-1502 | KFMC |
| Phase 2 study of 5 Days azacytidine priming prior to fludarabine, cytarabine and G-CSF combination for patients with relapsed or refractory AML. | King Fahad Medical City | Ongoing | Vidaza | 2 | Version 1.1 | KFMC |
| Phase 1 Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients with Retinal Disease due to MERTK Mutations | PSCDR | Completed | rAAV2 | 1 | rAAV2-VMD2-hMERTK | KFSH & RC-R |
| Perioperative Ischemic Evaluation-3 Tril (POISE-3) | KAIMRC | Ongoing | tranexamic acid | 3 | CT18/008/J | King Abdulaziz Medical City NG (Riyadh) |
| Perioperative Ischemic Evaluation-3 Tril (POISE-3) | KAIMRC | Ongoing | tranexamic acid | 3 | CT18/008/J | King Abdulaziz Medical City NG (Riyadh) |